Dong L M, Innerarity T L, Arnold K S, Newhouse Y M, Weisgraber K H
Gladstone Institute of Cardiovascular Disease, University of California, San Francisco, 94141-9100, USA.
J Lipid Res. 1998 Jun;39(6):1173-80.
Both apolipoprotein (apo) E2 and apoE-Leiden (tandem repeat of amino acids 121-127) are associated with type III hyperlipoproteinemia and bind defectively to low density lipoprotein receptors. Removing the carboxyl terminus of both variants (residues 192-299) increases receptor-binding activity, suggesting that the carboxyl terminus modulates activity. To identify the region(s) that modulated binding activity, we produced carboxyl-terminal truncations in apoE2 and apoE-Leiden (terminating at positions 191, 223, 244, and 272) and in apoE3 (terminating at positions 191, 223, and 244) and compared their receptor-binding activities as dimyristoylphosphatidylcholine (DMPC) discs. The results suggest that the entire carboxyl terminus up to residue 272, not a discrete smaller segment, is responsible for the modulation in apoE2. Intact apoE-Leiden and the 223 and 244 variants displayed similar activities (approximately 25% of apoE3's), but the 191 variant's activity was identical to that of intact apoE3. ApoE-Leiden and its truncated variants formed larger DMPC discs than did intact or truncated apoE3 or apoE2. These discs contained more apoE molecules than apoE3 discs, suggesting that the apparently normal binding activity of the apoE-Leiden 191 variant results from an increased number of apoE molecules and that the binding activity is actually defective. Direct comparison in a solid-phase assay revealed that the binding activity of the apoE-Leiden fragment was defective (51.4+/-9.4%). Thus, the defective binding of apoE-Leiden results from a direct effect of the seven amino acid repeat on receptor-binding activity rather than from an indirect effect operating through the carboxyl terminus as previously believed.
载脂蛋白(apo)E2和apoE-莱顿(氨基酸121 - 127的串联重复序列)均与III型高脂蛋白血症相关,且与低密度脂蛋白受体的结合存在缺陷。去除这两种变体的羧基末端(残基192 - 299)可增加受体结合活性,这表明羧基末端调节活性。为了确定调节结合活性的区域,我们在apoE2和apoE-莱顿(终止于位置191、223、244和272)以及apoE3(终止于位置191、223和244)中产生了羧基末端截短,并将它们作为二肉豆蔻酰磷脂酰胆碱(DMPC)圆盘比较其受体结合活性。结果表明,直至残基272的整个羧基末端而非离散的较小片段,是apoE2中调节作用的原因。完整的apoE-莱顿以及223和244变体表现出相似的活性(约为apoE3活性的25%),但191变体的活性与完整apoE3相同。apoE-莱顿及其截短变体形成的DMPC圆盘比完整或截短的apoE3或apoE2更大。这些圆盘比apoE3圆盘含有更多的apoE分子,这表明apoE-莱顿191变体明显正常的结合活性是由于apoE分子数量增加所致,且其结合活性实际上存在缺陷。在固相分析中的直接比较显示,apoE-莱顿片段的结合活性存在缺陷(51.4±9.4%)。因此,apoE-莱顿结合缺陷是由七个氨基酸重复序列对受体结合活性的直接影响导致 的,而非如先前认为的那样是通过羧基末端起间接作用。